A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation study of the study drug YH003 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH003 in subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: YH003
Adverse events (AEs), The safety will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0, up to 1 year after the last dosing|Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D), The MTD and/or RP2D will be determined based on the data of safety and tolerability, up to 1 year after the last dosing
This is an open-label, dose-escalation study of the study drug YH003 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH003 in subjects with advanced solid tumors.